Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. MacKenzie (GLASGOW, United Kingdom). Haemodynamic effects of exercise therapy in stable, optimally treated pulmonary arterial hypertension. 2395

Member's Comments

No comment yet.

Related content which might interest you: Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effects of oxygen supplementation during exercise on hemodynamic responses in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – New insights into evaluation and treatment of respiratory disease Year: 2020 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Deleterious effects of ß-blockers on exercise capacity and hemodynamics in portopulmonary hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Acute effects of oxygen supplementation during exercise in patients with pulmonary arterial hypertension Source: International Congress 2019 – Exercise physiopathology in various respiratory diseases Year: 2019 Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension Source: Eur Respir J 2013; 42: 414-424 Year: 2013 Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Hemodynamic correlates of exercise capacity in patients with pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 17s Year: 2005 Contrasting haemodynamic effects of exercise and saline infusion in older adults with pulmonary arterial hypertension Source: ERJ Open Res, 7 (1) 00183-2020; 10.1183/23120541.00183-2020 Year: 2021 Contrasting cardiopulmonary responses to incremental exercise in patients with schistosomiasis-associated and idiopathic pulmonary arterial hypertension with similar resting hemodynamic impairment Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Initial dual oral combination therapy in pulmonary arterial hypertension Source: Eur Respir J 2016; 47:1727-1736 Year: 2016